About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs

by Medindia Content Team on July 1, 2006 at 12:34 PM
Font : A-A+

Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs

Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance said that FDA's approval of REVLIMID (lenalidomide) offered a new oral drug option to the group of people suffering from multiple myeloma.

Advertisement

Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Multiple myeloma is the second most common blood cancer in the United States, affecting approximately 50,000 people. About 14,600 new cases of multiple myeloma are diagnosed each year and about 12,000 Americans are expected to die of multiple myeloma in 2006. In the REVLIMID (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3 or 4 adverse events were more frequent in patients who received the combination of REVLIMID (lenalidomide)/dexamethasone compared to placebo /dexamethasone.

'The FDA approval of REVLIMID offers a new oral therapeutic option to this particular group of patients with multiple myeloma,' said Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance for Celgene. REVLIMID will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Prevent Hacking of Medical Devices: FDA Sounds Alarm
Black Water: Benefits and Uses
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Multiple Myeloma 

Most Popular on Medindia

Post-Nasal Drip Blood - Sugar Chart Loram (2 mg) (Lorazepam) Find a Hospital Daily Calorie Requirements Vent Forte (Theophylline) Turmeric Powder - Health Benefits, Uses & Side Effects Drug Interaction Checker Calculate Ideal Weight for Infants Sanatogen

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use